DOI: 10.36347/sjams.2018.v06i03.044

Pages: 1035-1041

Multiple myeloma (MM) is a clonal plasma cell disorder that accounts for 1% of all malignancies and 15% of hematologic malignancies. The clinical course ranges from relatively indolent forms to frankly aggressive neoplasia. Although bone marrow study is one of the commonly used investigation for diagnosing multiple myeloma it’s staging is predominantly based on other laboratory and clinical features as in Salmon and Durie staging and International staging system. To date there is no reliable criterion for assessing the prognosis, based on the bone marrow studies. The current study is to emphasize the role of combined evaluation of bone marrow aspirate and trephine biopsies, not only for making the diagnosis but also for predicting the prognosis.